Short-Term Therapy with Luliconazole, a Novel Topical Antifungal Imidazole, in Guinea Pig Models of Tinea Corporis and Tinea Pedis

Abstract

Luliconazole is a novel topical antifungal imidazole with broad-spectrum and potent antifungal activity. The drug is under clinical development in the United States for management of dermatophytosis with a short-term treatment regimen. The present study was undertaken to investigate the clinical benefit of short-term therapy with luliconazole cream in guinea pig models of tinea corporis and tinea pedis induced with Trichophyton mentagrophytes. The dose-dependent therapeutic efficacy of topical luliconazole cream (0.02 to 1%), measured by macroscopic improvement of skin lesions and by fungal eradication as determined by a culture assay, was demonstrated using a tinea corporis model. The improvement in skin lesions seen with luliconazole cream was observed even at a concentration of 0.02%, and its efficacy at 0.1% was equal to that of 1% bifonazole cream. The efficacy of short-term therapy with 1% luliconazole cream, which is used for clinical management, was investigated using the tinea corporis model (4-and 8-day treatment regimens) and the tinea pedis model (7-and 14-day treatment regimens). The 1% luliconazole cream completely eradicated the fungus in half or less of the treatment time required for 1% terbinafine cream and 1% bifonazole cream, as determined by a culture assay for both models. These results clearly indicate that 1% luliconazole cream is sufficiently potent for short-term treatment for dermatophytosis compared to existing drugs. Luliconazole is expected to be useful in the clinical management of dermatophytosis.

Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide

“…Apoptosis induction was tested with the TUNEL-assay and SYTOX-green staining. In vivo activities of redS100A7 and TPEN as antifungal agents were investigated in guinea pig tinea pedis (28) and mouse Aspergillus lung infection models. All animal manipulations were approved by the ethical committee of Shimane University, Faculty of Medicine (approval no.…”

“…To investigate whether redS100A7 and TPEN also act in vivo, we generated a guinea pig model of tinea pedis (28). An ablated guinea pig foot was treated with redS100A7, TPEN, or the vehicle.…”

Safety and Tolerability of Luliconazole Solution 10-Percent in Patients with Moderate to Severe Distal Subungual Onychomycosis

“…Luliconazole is a novel, broad-spectrum, antifungal imidazole (12) approved in Japan for the treatment of superficial mycosis, such as dermatophytosis, candidiasis, and pityriasis versicolor (13). The MIC of luliconazole (MIC 90 ) has been found to be 4-to 1,000-fold lower than the MIC 90 s reported for a number of antifungals, including terbinafine, bifonazole, and lanoconazole (12,(14)(15)(16).…”

In vitro and in vivo antifungal activity, liver profile test, and mutagenic activity of five plants used in traditional Mexican medicine

“…Superficial mycoses are not life-threatening but are a serious problem for the quality of life because these infections can cause serious discomfort and cosmetic deformities (Koga et al, 2012). These diseases are observed worldwide and affect 20-25% of the world's population (Havlickova et al, 2008).…”

“…In addition, the dermatophyte resistance to antifungal drugs has resulted in the need for novel antimycotic agents with a broad spectrum and fewer side effects (Duraipandiyan et al, 2012;Girois et al, 2006;Khan and Ahmad, 2011). Thus, a more potent therapeutic drug that is capable of shortening treatment duration and improving patient adherence rate would be beneficial (Koga et al, 2012).…”